Insulin secretion is stimulated, glucagon and gastric acid secretion are inhibited, and GI transit and motility are decreased by incretin hormones, especially glucagon-like peptide-1 (GLP-1), which is released postprandially from L-cells lining the gut in response to food ingestion ( in vitro and in vivo , GLP-1 has been frequently demonstrated to reduce GI muscle activity via nerve-mediated mechanisms reliant on nitric oxide ( GLP-1 receptors, which are expressed in the central nervous system (CNS) in addition to peripheral tissues, are limited to neurons in the caudal nucleus of the solitary tract (NTS) and the ventrolateral medulla in the brainstem and hypothalamus ( Constipation-predominant IBS was linked to lower mucosal expression of GLP-1 receptors and serum GLP-1 concentrations ( This is the first systematic review and meta-analysis investigating GLP-1 agonists efficacy and safety in IBS patients
Studies show that a five-day loading protocol involving higher dosages (e.g
Following on from Betancourts rebrenaded, renamed but not reformulated pre-workout Bull NOX, now known as B-NOX
Neurotherapeutics 20(4):1229-1240
By targeting specific receptors and pathways, the compound can often achieve the desired therapeutic effects with a reduced risk of unintended consequences
The first GLP-1 drug, exenatide (Byetta), was developed after scientists discovered a compound in the saliva of the Gila monster, a venomous desert lizard
